| Literature DB >> 35664265 |
Yoshihisa Miyamoto1, Masao Iwagami2, Shotaro Aso3, Kazuaki Uda2, Kiyohide Fushimi4, Yoshifumi Hamasaki1, Masaomi Nangaku1, Hideo Yasunaga5, Kent Doi6.
Abstract
Background: The difference in outcomes of cancer surgery between patients with and without kidney failure with dialysis therapy (KFDT) remains uncertain.Entities:
Keywords: cancer; kidney failure with dialysis therapy (KFDT); mortality; postoperative complication; surgery
Year: 2022 PMID: 35664265 PMCID: PMC9155240 DOI: 10.1093/ckj/sfac005
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
FIGURE 1:Flow chart showing patient selection.
Patient characteristics in the matched cohorts
| Colorectal cancer | Lung cancer | Gastric cancer | Breast cancer | |||||
|---|---|---|---|---|---|---|---|---|
| Without KFDT | With KFDT | Without KFDT | With KFDT | Without KFDT | With KFDT | Without KFDT | With KFDT | |
|
| 2851 | 807 | 2216 | 579 | 1756 | 500 | 1387 | 362 |
| Male (%) | 2045 (71.7) | 580 (71.9) | 1717 (77.5) | 448 (77.4) | 1488 (84.7) | 415 (83.0) | 3 (0.2) | 3 (0.8) |
| Age (%) | ||||||||
| <65 years old | 534 (18.7) | 163 (20.2) | 385 (17.4) | 108 (18.7) | 291 (16.6) | 87 (17.4) | 631 (45.5) | 165 (45.6) |
| 65–74 years old | 1270 (44.5) | 341 (42.3) | 1187 (53.6) | 314 (54.2) | 815 (46.4) | 215 (43.0) | 496 (35.8) | 118 (32.6) |
| 75–84 years old | 935 (32.8) | 270 (33.5) | 626 (28.2) | 153 (26.4) | 585 (33.3) | 168 (33.6) | 234 (16.9) | 66 (18.2) |
| ≥85 years old | 112 (3.9) | 33 (4.1) | 18 (0.8) | 4 (0.7) | 65 (3.7) | 30 (6.0) | 26 (1.9) | 13 (3.6) |
| BMI (%) | ||||||||
| <18.5 | 241 (8.5) | 95 (11.8) | 163 (7.4) | 75 (13.0) | 133 (7.6) | 63 (12.6) | 127 (9.2) | 56 (15.5) |
| 18.5–24.9 | 1877 (65.8) | 556 (68.9) | 1457 (65.7) | 395 (68.2) | 1197 (68.2) | 349 (69.8) | 823 (59.3) | 233 (64.4) |
| 25.0–29.9 | 607 (21.3) | 124 (15.4) | 524 (23.6) | 95 (16.4) | 362 (20.6) | 73 (14.6) | 334 (24.1) | 52 (14.4) |
| ≥30 | 96 (3.4) | 22 (2.7) | 62 (2.8) | 9 (1.6) | 46 (2.6) | 9 (1.8) | 94 (6.8) | 18 (5.0) |
| Not available | 30 (1.1) | 10 (1.2) | 10 (0.5) | 5 (0.9) | 18 (1.0) | 6 (1.2) | 9 (0.6) | 3 (0.8) |
| Clinical stages (%) | ||||||||
| Stage 0–1 | 1500 (52.6) | 418 (51.8) | 1934 (87.3) | 493 (85.1) | 1357 (77.3) | 371 (74.2) | 789 (56.9) | 204 (56.4) |
| Stage 2 | 735 (25.8) | 215 (26.6) | 202 (9.1) | 62 (10.7) | 279 (15.9) | 89 (17.8) | 492 (35.5) | 127 (35.1) |
| Stage 3 | 616 (21.6) | 174 (21.6) | 80 (3.6) | 24 (4.1) | 120 (6.8) | 40 (8.0) | 106 (7.6) | 31 (8.6) |
| Types of anesthesia (%) | ||||||||
| General anesthesia | 959 (33.6) | 490 (60.7) | 644 (29.1) | 334 (57.7) | 422 (24.0) | 264 (52.8) | 1345 (97.0) | 351 (97.0) |
| General and epidural anesthesia | 1861 (65.3) | 300 (37.2) | 1545 (69.7) | 234 (40.4) | 1320 (75.2) | 232 (46.4) | 32 (2.3) | 2 (0.6) |
| Other | 31 (1.1) | 17 (2.1) | 27 (1.2) | 11 (1.9) | 14 (0.8) | 4 (0.8) | 10 (0.7) | 9 (2.5) |
| Fiscal years (%) | ||||||||
| 2010–11 | 482 (16.9) | 145 (18.0) | 366 (16.5) | 87 (15.0) | 387 (22.0) | 110 (22.0) | 200 (14.4) | 62 (17.1) |
| 2012–13 | 652 (22.9) | 164 (20.3) | 422 (19.0) | 130 (22.5) | 434 (24.7) | 127 (25.4) | 307 (22.1) | 90 (24.9) |
| 2014–15 | 746 (26.2) | 196 (24.3) | 636 (28.7) | 156 (26.9) | 460 (26.2) | 111 (22.2) | 407 (29.3) | 77 (21.3) |
| 2016–17 | 688 (24.1) | 204 (25.3) | 559 (25.2) | 148 (25.6) | 351 (20.0) | 109 (21.8) | 314 (22.6) | 94 (26.0) |
| 2018 | 283 (9.9) | 98 (12.1) | 233 (10.5) | 58 (10.0) | 124 (7.1) | 43 (8.6) | 159 (11.5) | 39 (10.8) |
| Current smoker (%) | 1402 (49.2) | 384 (47.6) | 1584 (71.5) | 391 (67.5) | 986 (56.2) | 258 (51.6) | 254 (18.3) | 61 (16.9) |
| Diabetes (%) | 573 (20.1) | 318 (39.4) | 451 (20.4) | 200 (34.5) | 370 (21.1) | 167 (33.4) | 115 (8.3) | 77 (21.3) |
| Myocardial infarction (%) | 59 (2.1) | 32 (4.0) | 37 (1.7) | 13 (2.2) | 35 (2.0) | 24 (4.8) | 6 (0.4) | 2 (0.6) |
| Cerebrovascular disease (%) | 118 (4.1) | 54 (6.7) | 95 (4.3) | 36 (6.2) | 70 (4.0) | 28 (5.6) | 14 (1.0) | 21 (5.8) |
| Chronic pulmonary disease (%) | 124 (4.3) | 20 (2.5) | 512 (23.1) | 69 (11.9) | 78 (4.4) | 15 (3.0) | 18 (1.3) | 8 (2.2) |
FIGURE 2:Differences in risks of primary outcomes between matched cohorts of patients with and without KFDT. Matched for age (within 5 years), sex, index fiscal year (within 3 years), primary cancer site, clinical cancer stage, surgical procedure and hospital to which admitted.
Differences in rates of secondary outcomes (all types of postoperative complications and emergency readmission) according to kidney failure status
| Colorectal cancer | Lung cancer | Gastric cancer | Breast cancer | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outcomes | Risk differences (95% CI) | Without KFDT, | With KFDT, | Risk difference (95% CI) | Without KFDT, | With KFDT, | Risk difference (95% CI) | Without KFDT, | With KFDT, | Risk difference (95% CI) | Without KFDT, | With KFDT, | |
| Postoperative | Heart failure | 2.6 (1.3–4.0) | 32 (1.1) | 30 (3.7) | 1.6 (0.2–3.0) | 25 (1.1) | 16 (2.8) | 2.7 (0.9–4.5) | 22 (1.3) | 20 (4.0) | 1.3 (0.1–2.5) | 1 (0.1) | 5 (1.4) |
| complications | Ischemic heart disease | 2.4 (1.1–3.7) | 28 (1.0) | 27 (3.3) | 2.6 (1.0–4.1) | 20 (0.9) | 20 (3.5) | 2.7 (1.0–4.5) | 22 (1.3) | 20 (4.0) | 1.3 (–0.1 to 2.7) | 5 (0.4) | 6 (1.7) |
| Pulmonary embolism | –0.1 (–0.2 to 0.0) | 2 (0.1) | 0 (0.0) | 0.1 (–0.3 to 0.4) | 2 (0.1) | 1 (0.2) | –0.1 (–0.3 to 0.1) | 2 (0.1) | 0 (0.0) | 0.0 (0.0–0.0) | 0 (0) | 0 (0) | |
| Heart rhythm abnormalities | 1.6 (0.1–3.1) | 74 (2.6) | 34 (4.2) | 0.1 (–2.1 to 2.3) | 124 (5.6) | 33 (5.7) | 2.0 (0.0–4.2) | 52 (3.0) | 25 (5.0) | 2.1 (0.1–4.0) | 17 (1.2) | 12 (3.3) | |
| Respiratory failure | 0.5 (–0.3 to 1.2) | 15 (0.5) | 8 (1.0) | –0.3 (–1.2 to 0.5) | 26 (1.2) | 5 (0.9) | 2.2 (0.7–3.8) | 14 (0.8) | 15 (3.0) | 0.5 (–0.3 to 1.2) | 1 (0.1) | 2 (0.6) | |
| Surgical site infection | 0.8 (–0.9 to 2.5) | 118 (4.1) | 40 (5.0) | –0.5 (–1.5 to 0.4) | 35 (1.6) | 6 (1.0) | 1.8 (–0.4 to 3.9) | 60 (3.4) | 26 (5.2) | –0.6 (–1.9 to 0.7] | 24 (1.7) | 4 (1.1) | |
| Anastomotic leakage | 0.5 (–1.0 to 2.0) | 95 (3.3) | 31 (3.8) | 0.3 (–0.3 to 0.7) | 2 (0.1) | 2 (0.3) | 2.7 (0.7–4.7) | 37 (2.1) | 24 (4.8) | 0.0 (0.0–0.0) | 0 (0) | 0 (0) | |
| Ileus | –2.0 (–3.4 to –0.7) | 136 (4.8) | 22 (2.7) | 0.0 (0.0–0.0) | 0 (0) | 0 (0) | –0.2 (–1.4 to 1.0) | 32 (1.8) | 8 (1.6) | 0.0 (0.0–0.0) | 0 (0) | 0 (0) | |
| Pneumonia | 0.4 (–0.4 to 1.1) | 18 (0.6) | 8 (1.0) | 1.3 (–0.6 to 3.3) | 82 (3.7) | 29 (5.0) | 1.1 (–0.4 to 2.6) | 27 (1.5) | 13 (2.6) | 0.2 (–0.4 to 0.8) | 1 (0.1) | 1 (0.3) | |
| Cerebral infarction | 0.3 (–0.2 to 0.9) | 8 (0.3) | 5 (0.6) | 0.7 (–0.1 to 1.6) | 7 (0.3) | 6 (1.0) | 1.4 (0.3–2.5) | 4 (0.2) | 8 (1.6) | 0.3 (–0.3 to 0.8) | 0 (0.0) | 1 (0.3) | |
| Postoperative drainage | 0.3 (–0.6 to 1.3) | 36 (1.3) | 13 (1.6) | 0.0 (0.0–0.0) | 0 (0) | 0 (0) | 0.8 (–0.5 to 2.2) | 24 (1.4) | 11 (2.2) | 0.0 (0.0–0.0) | 0 (0) | 0 (0) | |
| Emergent readmission | 2.2 (0.5–4.0) | 109 (3.8) | 49 (6.1) | 1.4 (–0.6 to 3.4) | 87 (3.9) | 31 (5.4) | 2.0 (–0.3 to 4.3) | 70 (4.0) | 30 (6.0) | 0.1 (–0.9 to 1.1) | 10 (0.7) | 3 (0.8) | |
Length of postoperative hospital stay
| Length of hospital stays (days), Median (25 percentile, 75 percentile) | |||
|---|---|---|---|
| Without KFDT | With KDFT |
| |
| Colorectal cancer | 12 (9, 16) | 14 (10, 21.5) | <0.001 |
| Lung cancer | 8 (6, 11.25) | 9 (7, 14) | <0.001 |
| Gastric cancer | 14 (11, 19) | 17 (13, 25.25) | <0.001 |
| Breast cancer | 6 (4, 9) | 7 (4, 9.75) | 0.079 |